Microbes play different roles in metabolism, local or systemic inflammation, and immunity, and the human microbiome in tumor microenvironment (TME) is important for modulating the response to immunotherapy in cancer patients. Renal cell carcinoma (RCC) is an immunogenic tumor, and immunotherapy is the backbone of its treatment. Correlations between the microbiome and responsiveness to immune checkpoint inhibitors have been reported. This review summarizes the recent therapeutic strategies for RCC and the effects of TME on the systemic therapy of RCC. The current understanding and advances in microbiome research and the relationship between the microbiome and the response to immunotherapy for RCC are also discussed. Improving our understandi...
The gut microbiome refers to microorganisms and their genetic material influencing local and systemi...
International audienceThe fine line between human health and disease can be driven by the interplay ...
Objective. To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in cle...
The gut microbiome has recently been proposed as a key player in cancer development and progression....
Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the develop...
The introduction of targeted therapy (TT) and immuno-oncology (IO) agents have revolutionized the tr...
Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for re...
Background: The development of immune checkpoint blockade (ICB) has revolutionized the clinical outc...
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Neverth...
The identification of new prognostic markers of renal cell carcinoma (RCC) is an urgent problem in o...
The role of the microbiome in immunology is a rapidly burgeoning topic of study. Given the increasin...
Background: Emerging evidence suggests that gut microbiota influences the clinical response to immun...
Colorectal cancer (CRC) constitutes the third most frequently reported malignancy in the male popula...
The gut microbiome refers to microorganisms and their genetic material influencing local and systemi...
International audienceThe fine line between human health and disease can be driven by the interplay ...
Objective. To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in cle...
The gut microbiome has recently been proposed as a key player in cancer development and progression....
Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the develop...
The introduction of targeted therapy (TT) and immuno-oncology (IO) agents have revolutionized the tr...
Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for re...
Background: The development of immune checkpoint blockade (ICB) has revolutionized the clinical outc...
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Neverth...
The identification of new prognostic markers of renal cell carcinoma (RCC) is an urgent problem in o...
The role of the microbiome in immunology is a rapidly burgeoning topic of study. Given the increasin...
Background: Emerging evidence suggests that gut microbiota influences the clinical response to immun...
Colorectal cancer (CRC) constitutes the third most frequently reported malignancy in the male popula...
The gut microbiome refers to microorganisms and their genetic material influencing local and systemi...
International audienceThe fine line between human health and disease can be driven by the interplay ...
Objective. To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in cle...